TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06158061

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: tryptase enzyme level
Description: In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: tryptase enzyme level
Description: In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy.
Study: NCT05939661

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Neoadjuvant radiation therapy : 5Gyx5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Operation: Total methorectum excision wiht radical lymph node dissection
Study: NCT04253548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer Support Mentorship Program
Description: iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
Study: NCT06544551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfacon-2
Description: Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfacon-2 placebo
Description: Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
Study: NCT04857307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: * Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points.
Study: NCT04191239

Intervention type: DEVICE
Intervention: GE ventilator with two different modes
Description: GE ventilator with two different modes

Intervention type: DEVICE
Intervention: GE ventilator with two different modes
Description: GE ventilator with two different modes
Study: NCT05402449

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
Study: NCT04584125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light
Description: A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Description: The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
Study: NCT05182814

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Blank
Study: NCT05391009

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TRT
Description: The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
Study: NCT05182814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Juice Drink
Description: Testing product
Study: NCT06147947

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
Description: Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists. There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG.
Study: NCT06238908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGGT003
Description: Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)
Study: NCT05435001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter ECG Monitoring
Description: Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D\[D/N\]) will be computed.
Study: NCT06465823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
Study: NCT05152966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation using the FARAPULSE™ Cardiac Ablation System Plus
Study: NCT05758610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETH-155008
Description: ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.
Study: NCT06318988

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation using Closure fast
Description: Thermal ablation technique

Intervention type: PROCEDURE
Intervention: Aethoxysclerol
Description: sclero-or foamsclerose

Intervention type: DRUG
Intervention: Daflon
Description: Venoactive drugs

Intervention type: DEVICE
Intervention: Compression stocking
Description: Compression
Study: NCT05045079

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior Vena Caval (IVC) Occlusion maneuver
Description: During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
Study: NCT05601401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0 mg/kg IV every 14 days
Study: NCT05969977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-1011
Description: PPI-1011 is a liquid oil with light yellow to amber color, clear to slightly opalescent and flows readily at room temperature. It is insoluble in water and miscible with dichloromethane and liquid coconut oil. It is a synthetic glycerolipid derivative, comprised of an assembly of naturally-occurring products including glycerol backbone, an ether-linked hexadecyl group at sn1 position, an all-cis-4, 7, 10, 13, 16, 19-docosahexaenoyl group at sn2 position, and a lipoyl group at sn3 position. It was designed as a plasmalogen precursor and is similar in structure to naturally occurring alkyl-diacyl lipids with the primary difference being the presence of a lipoic acid moiety at the sn3 position. PPI-1011 is formulated in liquid coconut oil containing 0.1% 1-thioglycerol as an antioxidant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06212700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Exercise
Description: Aerobic (HIIT) Endurance Respiratory Muscle Strength Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Exercise
Description: Aerobic Muscle Strength Walking Program Education

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Nutrition
Description: Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postoperative Nutrition
Description: Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Psychology
Description: CBT skills Skills training Emotional validation Behavioural activation Psycho-education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Psychology
Description: CBT skills Skills training Emotional validation Behavioural activation Psycho-education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Nursing
Description: Comorbidities Managing pain Wound care Complications Surgical education ERAS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Nursing
Description: Managing pain Cardiovascular stability Wound care Bowel function/Stoma Complications Education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Peer Support Group
Description: Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Peer Support Group
Description: Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
Study: NCT05502315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 40 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg by infusion
Study: NCT05958290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of antibiotics
Description: Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
Study: NCT05771324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby-Led Weaning (BLW)
Description: BLW trainings given to mothers for 6-12 month old babies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Complementary Feeding (TCF)
Description: TCF trainings given to mothers for 6-12 month old babies
Study: NCT06299878

Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiota analysis
Description: Patients with resectable stage IIIB-D melanoma will have a lymph node core biopsy to confirm metastatic lesions, following standard procedures. Additionally, a portion of the tumor tissue will be preserved for biomarker analysis. Participants will then be instructed to submit fecal samples and complete a dietary questionnaire before receiving three doses of PD1 monotherapy, in accordance with the center\&#39;s routine practice, typically spanning 6-10 weeks. Between weeks 10 and 12, a radiological assessment of the response will be conducted. Following this, participants will undergo regional lymphadenectomy, and the pathological response will be evaluated. After surgery, patients will be placed on adjuvant therapy for 12 months as per routine practice of the center . Subsequently, they will be monitored for five years, adhering to the institution\&#39;s standard follow-up protocol.
Study: NCT05729750

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans abdominal ultrasound for assess biophysical profile
Description: The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Trans abdominal ultrasound for assess biophysical profile
Description: The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
Study: NCT05465915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Patients are treated with ECT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Patients are treated with ECT.
Study: NCT05747079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
Study: NCT06562894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)
Study: NCT05747079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional delayed anterior cruciate ligament reconstruction
Description: If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate anterior cruciate ligament reconstruction
Description: No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury.
Study: NCT05128227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharm-SAVES
Description: A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharm-SAVES
Description: A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive video cases
Description: Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
Study: NCT06562894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily (QD)
Study: NCT05277727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan 500mg
Description: 1 capsule to be taken twice daily with food (morning and evening).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule to be taken twice daily with food (morning and evening).
Study: NCT05432154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Film forming silicone gel (7-0940)
Description: Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances.